New drug trial aims to outsmart lung Cancer's resistance
NCT ID NCT05463224
Summary
This study is testing a drug called Lazertinib as the first treatment for people with advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutations). The main goals are to see how well the drug controls the cancer, how safe it is, and to understand why the cancer might eventually stop responding to it. Researchers will enroll about 150 patients who have not received any prior targeted therapy for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, Gangnamgu, 06351, South Korea
Conditions
Explore the condition pages connected to this study.